TCGA cohort | |
---|---|
No. of patients | 1076 |
Age (median) | 58 |
Sex (%) | |
Female | 1076 (100%) |
Male | 0 (0%) |
Stage/grade (%) | |
I/1 | 183 (17%) |
II/2 | 608 (56.5%) |
III/3 | 242 (22.5%) |
IV | 20 (1.9%) |
Unknown | 23 (2.1%) |
ER status (%) | |
Positive | 806 |
Negative | 240 |
Unknown | 30 |
PR status (%) | |
Positive | 698 |
Negative | 345 |
Unknown | 33 |
Her2 status (%) | |
Positive | 161 |
Negative | 564 |
Unknown | 351 |
Therapy | |
Chemotherapy | 490 |
Immunotherapy | 4 |
Hormone Therapy | 269 |
Targeted Molecular therapy | 5 |
Other | 308 |
Survival status OS days (median) | 1256 |